Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 2/20 | 0.33 |
| ▸ | EDNRA | P25101 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855337 | 0.79 | MAOA (0.37) | POLBMEN1KMT2AMAPK1HDAC3 | |
| SCHEMBL8011185 | 0.76 | ALDH1A1 (0.46) | EDNRBEDNRAPOLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL31290829 | 0.75 | NOS1 (0.31) | GPR3HTR2A | |
| SCHEMBL2230905 | 0.75 | MAPT (0.48) | EDNRBEDNRAPOLBMEN1KMT2A | |
| SCHEMBL7892212 | 0.74 | ALDH1A1 (0.41) | POLBMEN1KMT2AHTR2AALDH1A1 | |
| SCHEMBL8554351 | 0.71 | ALDH1A1 (0.43) | POLBMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL7248118 | 0.71 | RAB9A (0.46) | EDNRBEDNRAPOLBMEN1KMT2A | |
| SCHEMBL7884961 | 0.71 | MAOB (0.40) | POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL2182063 | 0.71 | KMT2A (0.46) | POLBMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL2203803 | 0.70 | HPGD (0.36) | MEN1KMT2ACYP1A2MAPK1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2021-11-02 | — | — | US | disclosed |
| US-20210322475-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UAB RESEARCH FOUNDATION | 2021-10-21 | — | — | US | disclosed |
| EP-3877514-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | In8bio, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20210046072-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | KING'S COLLEGE LONDON (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10799501-B2 | Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L | KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20200172901-A1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | VALERIO THERAPEUTICS (FR) | 2020-06-04 | — | — | US | disclosed |
| US-10563197-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2020-02-18 | — | — | US | disclosed |
| US-20190076427-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST (GB) | 2019-03-14 | — | — | US | disclosed |
| US-20180362972-A1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | VALERIO THERAPEUTICS (FR) | 2018-12-20 | — | — | US | disclosed |
| EP-3370774-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | King's College London (GB) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017077326-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | KING'S COLLEGE LONDON (GB) | 2017-05-11 | — | — | WO | disclosed |
| US-20160208339-A1 | BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS | KING'S COLLEGE LONDON (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20120135983-A1 | DNA Damage Repair Inhibitors for the Treatment of Cancer | The Institute of Cancer Reseach | 2012-05-31 | — | — | US | disclosed |
| US-8143241-B2 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-03-27 | — | — | US | disclosed |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA R&D (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | EDNRB 2661/4885EDNRA 2421/4885POLB 291/4885 |
| US-20200172901-A1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | PARP10, PARP1, PARP3 | EDNRB 2661/4885EDNRA 2421/4885POLB 291/4885 |
| US-20120135983-A1 | DNA Damage Repair Inhibitors for the Treatment of Cancer | MRE11, ERCC4, PARP2 | EDNRB 2332/4885EDNRA 3306/4885POLB 46/4885 |
| US-20210046072-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | PARP3, PARP11, GSK3A | EDNRB 4462/4885EDNRA 4576/4885POLB 850/4885 |
| US-10563197-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | EDNRB 2661/4885EDNRA 2421/4885POLB 291/4885 |
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | EDNRB 1431/4885EDNRA 1781/4885POLB 2396/4885 |
| US-10799501-B2 | Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L | PARP3, PARP11, GSK3A | EDNRB 4462/4885EDNRA 4576/4885POLB 850/4885 |
| US-20180362972-A1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | PARP10, PARP1, PARP3 | EDNRB 2661/4885EDNRA 2421/4885POLB 291/4885 |
| US-20190076427-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | PARP3, PARP11, GSK3A | EDNRB 4462/4885EDNRA 4576/4885POLB 850/4885 |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | CHEK1, CHEK2, PARP1 | EDNRB 4084/4885EDNRA 4296/4885POLB 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.